iXensor

iXensor is a pioneering force in the field of mobile health, effectively transforming standard smartphones into high-performing, lab-grade medical diagnostic devices for point-of-care and at-home self-testing solutions. Their flagship product, PixoTest®, achieved the remarkable feat of becoming the world's first FDA-approved smartphone camera-based blood test in 2017. The company's roots trace back to a fortuitous meeting of its founding team at Stanford University in 2011. Recognizing the potential of smartphones in revolutionizing the future of healthcare, iXensor officially commenced its operations in 2012, establishing its base in Silicon Valley before incorporating in Taipei, Taiwan. Supported by a multidisciplinary team with expertise spanning medical engineering, biochemistry, and information technology, iXensor is dedicated to developing cutting-edge digital health solutions that promise to redefine tomorrow's connected healthcare. Their product portfolio, which includes offerings in Women's Health, Chronic, and Infectious Diseases, relies on their proprietary PixoTech® platform, safeguarded by over 50 international patents. This platform serves as the foundation for their imminent growth phase, embodying a platform-as-a-service model. The company has garnered international acclaim, winning numerous awards for their innovation. Additionally, iXensor's progress has been accelerated through collaborations with prominent entities such as the Merck Accelerator, Plug & Play's Creasphere, and Johnson & Johnson Innovation's JLABs. With a clear mission to facilitate data-driven healthcare through instant medical tests and seamless data synchronization, iXensor envisions a future where quality healthcare is accessible and timely for all. As the company continues to make strides in mobile health, it remains a compelling prospect for potential venture capital investment.